Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

G Mark Foletta

Affiliations

  • Evp & Chief Financial Officer at Tocagen Inc (TOCA), 2019-10-05
  • Director at Dexcom Inc (DXCM), 2019-06-04
  • Director at Amn Healthcare Services Inc (AMN), 2019-04-19
  • Director at Regulus Therapeutics Inc. (RGLS), 2017-12-07
  • Interim Cfo at Biocept Inc (BIOC), 2015-09-02
  • Director at Ambit Biosciences Corp (AMBI), 2014-11-12
  • Svp, Chief Financial Officer at Amylin Pharmaceuticals Inc (AMLN), 2012-08-10
  • Director at Anadys Pharmaceuticals Inc (ANDS), 2011-05-27
Insider Trading: Purchases See All
Company Symbol Price Amount Relationship Remaining Holdings Date Form 4
TOCA $4.30 5,000 Officer 15,042 2019-05-28 Filing
TOCA $10.00 5,000 Officer 5,000 2017-04-19 Filing
RGLS $7.64 10,000 Director 10,000 2015-08-13 Filing
Insider Trading: Sales See All
Company Symbol Price Amount Relationship Remaining Holdings Date Form 4
DXCM $122.73 400 Director 13,095 2019-05-15 Filing
DXCM $121.88 500 Director 13,495 2019-05-15 Filing
DXCM $118.65 100 Director 13,995 2019-05-15 Filing
DXCM $119.36 599 Director 14,095 2019-04-15 Filing
DXCM $118.88 301 Director 14,694 2019-04-15 Filing